X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Novartis India Limited enters into an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories for a few of its Established Medicines which includes the Voveran® range, the Calcium range and Methergine®.
Lead Product(s): Diclofenac
Therapeutic Area: Neurology Product Name: Voveran
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2022
Details:
The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
Lead Product(s): Diclofenac
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chromocell Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 27, 2024
Details:
DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Lead Product(s): Diclofenac
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-PDM1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.
Lead Product(s): Diclofenac
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Virpax intends to use the net proceeds from the offering to fund research and development of the Epoladerm, Probudur, Envelta and AnQlar indications and other development programs in clinical trial.
Lead Product(s): Diclofenac
Therapeutic Area: Musculoskeletal Product Name: Epoladerm
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
